BioCryst Pharma Promotes Charles Gayer to Chief Commercial Officer

BioCryst Pharmaceuticals (NASDAQ: [[ticker:BCRX]]) has promoted Charles Gayer to chief commercial officer. Gayer joined the Durham, NC-based drug developer in 2015 as vice president of global strategic marketing. His experience also includes positions at Talecris and GlaxoSmithKline (NYSE: [[ticker:GSK]]). BioCryst is preparing for the expected commercial launch of berotralstat, a drug that has been submitted for FDA review for preventing the swelling attacks associated with the rare disease hereditary angioedema.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan